Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Dihexa | GHRP-6 | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 10-20 mg daily via oral or sublingual administration. | Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection. |
| Timing | Morning dosing preferred. Can be taken with or without food (orally active). | On empty stomach, 30+ minutes before meals. Bedtime dose most important. The strong hunger effect makes pre-meal timing practical. |
| Cycle Duration | 2-4 week cycles with equal rest periods. Long-term safety data is extremely limited. | 8-16 week cycles. |
| Evidence Level | animal_plus_anecdotal | moderate_human |
Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is an orally active, blood-brain barrier-permeable oligopeptide derived from angiotensin IV. It binds hepatocyte growth factor (HGF) with high affinity, inhibiting HGF dimerization and synergistically promoting c-Met receptor phosphorylation and signaling. Activation of HGF/c-Met drives procognitive effects through increased dendritic arborization, spinogenesis, and synaptogenesis via the PI3K/AKT signaling pathway. Research indicates it is approximately 10 million times more potent than BDNF for new synapse formation.
Research indicates 10-20 mg daily via oral or sublingual administration.
Morning dosing preferred. Can be taken with or without food (orally active).
2-4 week cycles with equal rest periods. Long-term safety data is extremely limited.
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that stimulates GH release through activation of the growth hormone secretagogue receptor (GHS-R1a/ghrelin receptor) on pituitary somatotrophs. It acts via dual sites — pituitary and hypothalamic — possibly involving regulatory factors beyond GHRH and somatostatin. GHRP-6 also stimulates ghrelin-mediated appetite signaling, increases cortisol and prolactin release, and has demonstrated cytoprotective properties including cardioprotection.
Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.
On empty stomach, 30+ minutes before meals. Bedtime dose most important. The strong hunger effect makes pre-meal timing practical.
8-16 week cycles.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →